The Prognostic Value of the Metabolic Syndrome in Colon Cancer Patients

Can A*, Aslan F, Alacacıoglu A, Kucukzeybek Y, Erten C, Çokmert S, Demir L, Dirican A, Bayoglu IV, Akyol M and Tarhan MO

Background: The aim of this study is to investigate the relationship between the Metabolic Syndrome the parameters of it and the manifest prognostic factors of the Colon Cancer in newly-diagnosed phase 2-4 colon cancer patients.

Patients and Method: 104 newly-diagnosed and phase 2-4 Colon Cancer patients were prospectively included in the study at Ä°zmir Atatürk Training and Research Hospital Medical Oncology Policlinic between June 2010 and December 2012. Demographic, anthropometric and laboratory data belonging to the patients were recorded. To detect the presence of Metabolic Syndrome at the time of the diagnosis, patients were tested for hunger blood glucose, LDL, HDL, triglyceride, total cholesterol levels besides the metric measurement of the waist and hip perimeters.

To detect the presence of hypertension, blood pressures were measured from both arms by a physician using a sphygmomanometer. Heights and weights of the patients were measured to calculate their BMI (Body Mass Index). The frequency of Metabolic Syndrome was searched in colon cancer patients. The clinical phase, lymph node involvement, distant metastasis, histologic grade, perineural invasion, and lymphovascular invasion were recorded. Frequency of the metabolic syndrome was looked into in colon cancer patients. The frequency of the Metabolic Syndrome parameters in colon cancer patients were looked into. Patients were divided into two groups as Colon Cancer patients with and without Metabolic Syndrome. Prognostic factors of the Colon Cancer were compared between these two groups.

Results: The average age of the patients included in the study was 61.67 ± 10.09 in those with Metabolic Syndrome and 58.45 ± 10.39 in those without Metabolic Syndrome. 47.1% of patients suffered from Metabolic Syndrome. 61.2% and 38.8% of colon cancer patients with Metabolic Syndrome were female and male, respectively. Parameters of the Metabolic Syndrome revealed that manifest prognostic values (tumor size, lymph node involvement, metastatic status, tumor grade, differentiation, obstruction, perforation, perineural invasion, lymphovascular invasion, tumor localization) at the time of the diagnosis between the Colon Cancer patient groups with newly-diagnosed Metabolic Syndrome and those without the Metabolic Syndrome were not found to be statistically different.

Conclusions: In some of the former studies, it was found that Metabolic Syndrome was negatively correlated with prognostic factors in Colon Cancer patients. Due to the insufficient number of patients, the lack of information on the duration of the Metabolic Syndrome in patients and the insufficient time for observation in our study, we were not able to draw clear-cut conclusions regarding the relationship between the newly-diagnosed colon cancer and the Metabolic Syndrome. Further research on this subject that includes a higher number of patients is required.